A5102893072- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Statistical Methods in Clinical Trials
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Advanced Causal Inference Techniques
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Research Studies
- Fungal Infections and Studies
- Pneumocystis jirovecii pneumonia detection and treatment
- Sphingolipid Metabolism and Signaling
- HIV/AIDS Research and Interventions
- Brain Metastases and Treatment
- Healthcare Systems and Technology
- Ion Transport and Channel Regulation
- Lysosomal Storage Disorders Research
- Pharmaceutical studies and practices
- Glioma Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- HIV/AIDS drug development and treatment
- Antifungal resistance and susceptibility
Northwestern University
2023
MedStar Harbor Hospital
2019
Massachusetts General Hospital
2012-2016
Sarah Cannon
2012
Tennessee Oncology
2012
The Barbara Ann Karmanos Cancer Institute
2012
Dana-Farber Cancer Institute
2012
Memorial Sloan Kettering Cancer Center
2012
Indiana University Health
2012
Indiana University – Purdue University Indianapolis
2012
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of trastuzumab with cytotoxic activity microtubule-inhibitory agent DM1. The antibody and are conjugated by means a stable linker.
To determine whether the antibody-drug conjugate trastuzumab emtansine (T-DM1), which combines human epidermal growth factor receptor 2 (HER2) -targeted delivery of potent antimicrotubule agent DM1 with antitumor activity trastuzumab, is effective in patients HER2-positive metastatic breast cancer (MBC) who have previously received all standard HER2-directed therapies.In this single-arm phase II study, T-DM1 3.6 mg/kg was administered intravenously every 3 weeks to MBC had prior treatment...
Abstract Purpose: HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC. Patients Methods: Eligible had NSCLC (centrally tested IHC) received previous platinum-based chemotherapy targeted case EGFR mutation or ALK gene rearrangement. were divided into cohorts based on...
Oncology drug development increasingly relies on single‐arm clinical trials. External controls ( EC s) derived from electronic health record EHR ) databases may provide additional context. Patients a US ‐based oncology database were aligned with patients randomized controlled trials RCT and trial‐specific eligibility criteria applied to the dataset. Overall survival OS in ‐derived control arm was compared experimental arm. The primary outcome , defined as time randomization or treatment...
Abstract BACKGROUND: We conducted a phase 1, multicenter, open‐label, dose‐escalation study (TDM3569g) to assess the safety, tolerability, and pharmacokinetics of single‐agent trastuzumab emtansine (T‐DM1) administered weekly once every 3 weeks in patients with HER2‐positive metastatic breast cancer previously treated trastuzumab. The dose results are described here. METHODS: Patients were escalating doses T‐DM1 weekly, starting at 1.2 mg/kg. Additional enrolled maximum tolerated (MTD)...
LBA1 The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Sunday edition ASCO Daily News.
Proton therapy offers dosimetric advantage of decreased dose to non-target tissues. This study explored the potential benefits proton radiation versus photon based intensity modulated (IMRT) for patients with low grade gliomas (LGG) through comparison and biological modeling radiation-induced toxicities. Eleven were treated fractionated on a prospective protocol assessing feasibility treatment toxicity in LGG. IMRT plans created each patient using same CT planning data set defined...
LBA1 Background: T-DM1 is an antibody-drug conjugate comprising T, a stable linker, and the potent cytotoxic agent DM1; it incorporates antitumor activities of T HER2-targeted delivery DM1. Methods: EMILIA randomized study vs XL, only approved combination for T-refractory HER2+ MBC. Patients (pts) received (3.6 mg/kg IV q3w) or X (1000 mg/m 2 PO bid, days 1–14 + L (1,250 mg daily) until progressive disease (PD) unmanageable toxicity. Pts had confirmed MBC (IHC3+ and/or FISH+), prior therapy...
8509 Background: T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer. We report primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts with previously treated HER2-overexpressing mNSCLC who received single-agent T-DM1. Methods: Eligible had and were platinum-based therapy. Pts 3.6 mg/kg every 3 weeks analyzed in cohorts based on centrally determined HER2 status (immunohistochemistry [IHC]2+ vs IHC3+ [≥10% cells stained 2+ or 3+...
Abstract Purpose: The utility of real-world data (RWD) for use as external controls in drug development is informed by studies that replicate trial control arms different endpoints. purpose this study was to from four non–small cell lung cancer (NSCLC) randomized controlled trials (RCT) analyze overall survival (OS), progression-free (PFS), and response rate (ORR) using RWD. Patients Methods: This used RWD a nationwide de-identified database clinico-genomic OS, PFS, ORR endpoints the...
The effect of mixing the contents efavirenz capsules (sprinkles) with a small amount food on bioavailability and pharmacokinetics in healthy adults was evaluated. In randomized, three-period, crossover study, 24 adult subjects were divided equally into two groups. Group I received treatments A, B, C, those group II D, E. Treatment A three 200-mg intact under fasting conditions. Treatments E capsule mixed teaspoons applesauce, grape jelly, yogurt, or infant formula, respectively. single dose...
<p>Supplementary appendix</p>
Abstract Background Musculoskeletal (MSK) pathologies significantly affect the rehabilitation course for patients admitted to an inpatient facility (IRF). The impact of a specialized MSK consult service has not been previously evaluated. Objective To assess demographics, pathologies, and on pain scores who were evaluated by service. Design Retrospective descriptive analysis at IRF Setting Academic IRF. Participants 230 over 4.5 years. Interventions composed sports medicine fellowship‐trained...
TPS2087 Background: Making personalized diagnostics and treatments a reality for every cancer patient necessitates comprehensively capturing the journey. Real-world data has shown promise future of clinical research advancing precision medicine. However, certain limitations exist such as quality management well bias confounding factors associated with retrospective analyses. We present multi-stakeholder platform to prospectively collect link real-world clinico-genomic, imaging, outcomes...
6578 Background: Overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) is an established early efficacy endpoint used clinical trials. Comparison of real world tumor (rwTR) and ORR can provide important insights for health professionals, regulators, researchers. Methods: We retrospectively analyzed electronic records (EHRs) patients with metastatic or recurrent NSCLC treated epidermal growth factor receptor (EGFR)-targeted therapy (afatinib erlotinib) a...
Cryptococcus is an encapsulated fungal organism often implicated in central nervous system and pulmonary disease patients with AIDS or other immunocompromising diseases. However, immunocompetent hosts can also be infected. In these cases, symptoms are generally mild common radiographic findings include small, well-defined, smoothly marginated nodules. We present a case of 31-year-old man without any factors found to have Cryptococcal infection presenting as large lung mass.
<p>Supplementary appendix</p>
<div>AbstractPurpose:<p>HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC.</p>Patients Methods:<p>Eligible had NSCLC (centrally tested IHC) received previous platinum-based chemotherapy targeted case <i>EGFR</i>...
<div>AbstractPurpose:<p>HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with previously treated advanced HER2-overexpressing NSCLC.</p>Patients Methods:<p>Eligible had NSCLC (centrally tested IHC) received previous platinum-based chemotherapy targeted case <i>EGFR</i>...
Supplementary Figure from Replication of Overall Survival, Progression-Free and Response in Chemotherapy Arms Non–Small Cell Lung Cancer Trials Using Real-World Data